MDT · News · 20261107N
Renal Denervation Evidence
Medtronic plc · 2026-11-07 · Importance 31 · Surprise 42 · In source text
The article cites positive study results for Medtronic’s Symplicity Spyral renal denervation system and wider FDA labeling. It suggests these developments could support future procedure volumes and cash inflows from Medtronic’s hypertension franchise. It provides no study data, procedure-volume estimates, or further details about the labeling.
Key facts
- Medtronic has wider FDA labeling for its hypertension franchise. source
- Medtronic reported positive Symplicity Spyral study results. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Medtronic has wider FDA labeling for its hypertension franchise. |